Overview
Overview
Chonluten is a short bioregulatory tripeptide (Glu‑Asp‑Gly) studied for its effects on bronchopulmonary tissue and inflammatory pathways in monocyte/macrophage cell models[1]. As a small peptide with poor oral stability, subcutaneous injection is the indicated parenteral route[2]. This educational protocol presents a once‑daily subcutaneous approach using a practical dilution for clear insulin‑syringe measurements. Reconstitute: Add 3.0 mL bacteriostatic water → 6.67 mg/mL concentration. Typica
- Category
- Longevity
- Routes
- subcutaneous
Mechanism
Chonluten
Mechanism of action
Mechanism of action
Chonluten (Glu‑Asp‑Gly) is a short bioregulatory peptide studied within the Khavinson peptide bioregulator framework targeting bronchopulmonary tissues [1] . In vitro research using monocyte/macrophage (THP‑1) cell models indicates Chonluten may modulate proliferative activity and inflammatory pathways at concentrations in the nanomolar range [1] . Short peptides such as Chonluten typically exhibit poor oral bioavailability due to enzymatic degradation and limited mucosal permeability, supporting subcutaneous administration as the preferred route [2] [5] .
Key research findings
- 01
In vitro (human cell line): In the only PubMed-indexed study reporting Chonluten-specific data, the tripeptide Glu-Asp-Gly (designation T-34, described as derived from bronchial epithelial tissue) was tested at 100 ng/mL on human THP-1 monocytes/macrophages and reduced lipopolysaccharide (LPS)-stimulated tumor necrosis factor (TNF) and interleukin-6 (IL-6) release, an anti-inflammatory / 'TNF-tolerance' pattern (Avolio et al., 2022, Int J Mol Sci; PMID 35408963; doi:10.3390/ijms23073607).
- 02
In vitro (signaling): In the same study, Chonluten increased tyrosine phosphorylation of MAPK/ERK1/2 (a proliferative-signaling readout), while its effect on monocyte adhesion to LPS-activated endothelial (HUVEC) cells was variable. These readouts were broadly shared with the four other Khavinson peptides tested, so they are not unique to Chonluten (Avolio et al., 2022; PMID 35408963; doi:10.3390/ijms23073607).
- 03
Context / classification (review): Chonluten is one of the 'Khavinson ultrashort peptides' from the St. Petersburg Institute of Bioregulation and Gerontology. The class-level hypothesis that such short peptides influence gene expression (cell/nuclear entry, DNA/histone interaction) is documented for other family members, not for the Glu-Asp-Gly tripeptide specifically (Khavinson et al., 2021, Molecules; PMID 34834147; doi:10.3390/molecules26227053).
- 04
Non-conflation caution (review): Peer-reviewed lung-cell differentiation gene effects in the Khavinson literature (NKX2-1, SCGB1A1, SCGB3A2, FOXA1, FOXA2) are attributed to a different peptide, the tetrapeptide AEDL (Bronchogen) — NOT to Chonluten (EDG). Online vendor sources frequently conflate the two (Khavinson et al., 2021, Molecules; PMID 34834147; doi:10.3390/molecules26227053).
- 05
Scope / evidence gap: No PubMed-indexed animal-model or human studies specific to Chonluten (Glu-Asp-Gly) were located. Respiratory-regeneration, mucin/ciliary, antioxidant/heat-shock, and anti-aging claims for this tripeptide appear only in non-peer-reviewed vendor/marketing material and are not supported by indexed primary research.
Primary source: The peer-reviewed evidence specific to Chonluten (tripeptide Glu-Asp-Gly, T-34) is very limited — essentially a single 2022 in vitro immunology study in a human monocyte/macrophage cell line (Avolio et al., Int J Mol Sci; PMID 35408963), set within the broader, largely single-group 'Khavinson ultrashort peptide' literature whose tissue-specific and gene-regulation claims rest mainly on other family members. No animal-model or human clinical studies specific to this tripeptide were identified in PubMed, so this remains a research-grade compound with limited peer-reviewed data.
Researched Effects
Researched benefits
Areas of active research and investigation. Results may vary and are based on preclinical or early clinical data.
May support bronchopulmonary tissue function and respiratory cell regulation based on bioregulator peptide research[1].
Cell‑culture studies suggest modulation of inflammatory and proliferative pathways in monocyte/macrophage models[1].
Short peptides in this class generally show favorable tolerability profiles in preclinical settings[5].
Occasional mild injection‑site reactions (redness/itch) may occur with subcutaneous administration.
Protocol Reference
Protocol reference
Commonly cited research range: 250–4000 mcg, daily.
Reference figures reported in the research literature — not a dosing recommendation. For interactive vial math and scheduling, see the Calculator and Schedule tabs.
Cited protocol & reconstitution guide
Source-backed reference fields by phase, including any volume fields authored in the cited guide.
Weeks 1–2
250 mcg (0.25 mg)
Weeks 3–4
500 mcg (0.5 mg)
Weeks 5–6
1,000 mcg (1 mg)
Weeks 7–8
1,500 mcg (1.5 mg)
Weeks 9–10
2,000 mcg (2 mg)
Weeks 11–12
3,000 mcg (3 mg)
Weeks 13–14
4,000 mcg (4 mg)
Weeks 15–16
4,000 mcg (4 mg)
| Phase | Reference amount | Units / volume |
|---|---|---|
| Weeks 1–2 | 250 mcg (0.25 mg) | 3.75 units (0.0375 mL) |
| Weeks 3–4 | 500 mcg (0.5 mg) | 7.5 units (0.075 mL) |
| Weeks 5–6 | 1,000 mcg (1 mg) | 15 units (0.15 mL) |
| Weeks 7–8 | 1,500 mcg (1.5 mg) | 22.5 units (0.225 mL) |
| Weeks 9–10 | 2,000 mcg (2 mg) | 30 units (0.30 mL) |
| Weeks 11–12 | 3,000 mcg (3 mg) | 45 units (0.45 mL) |
| Weeks 13–14 | 4,000 mcg (4 mg) | 60 units (0.60 mL) |
| Weeks 15–16 | 4,000 mcg (4 mg) | 60 units (0.60 mL) |
Storage & Handling
Storage requirements(typical for most peptides)
Can be stored for extended periods. Protect from moisture.
Store in refrigerator door. Never freeze after reconstitution.
Label vials with reconstitution date. Discard if cloudy.
Reconstitution steps
- 01🌡️Draw 3.0 mL bacteriostatic water with a sterile syringe.
- 02🧴Inject slowly down the vial wall; avoid foaming.
- 03💉Gently swirl/roll until dissolved (do not shake).
- 04💧Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
- 05🔄Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.
Additional storage notes
Refrigerate at 4 °C (39.2 °F) in dry, dark conditions.
Store at −20 °C (−4 °F) or colder; minimize moisture exposure.
Refrigerate at 2–8 °C (35.6–46.4 °F); use within days to weeks and avoid freeze–thaw .
Allow vials to reach room temperature before opening to reduce condensation uptake.
Clinical Evidence
Clinical evidence
Preclinical cell-model research describes anti-inflammatory and tissue-protective activity.
The peer-reviewed evidence specific to Chonluten (tripeptide Glu-Asp-Gly, T-34) is very limited — essentially a single 2022 in vitro immunology study in a human monocyte/macrophage cell line (Avolio et al., Int J Mol Sci; PMID 35408963), set within the broader, largely single-group 'Khavinson ultrashort peptide' literature whose tissue-specific and gene-regulation claims rest mainly on other family members. No animal-model or human clinical studies specific to this tripeptide were identified in PubMed, so this remains a research-grade compound with limited peer-reviewed data.
- 01In vitro (human cell line): In the only PubMed-indexed study reporting Chonluten-specific data, the tripeptide Glu-Asp-Gly (designation T-34, described as derived from bronchial epithelial tissue) was tested at 100 ng/mL on human THP-1 monocytes/macrophages and reduced lipopolysaccharide (LPS)-stimulated tumor necrosis factor (TNF) and interleukin-6 (IL-6) release, an anti-inflammatory / 'TNF-tolerance' pattern (Avolio et al., 2022, Int J Mol Sci; PMID 35408963; doi:10.3390/ijms23073607).
- 02In vitro (signaling): In the same study, Chonluten increased tyrosine phosphorylation of MAPK/ERK1/2 (a proliferative-signaling readout), while its effect on monocyte adhesion to LPS-activated endothelial (HUVEC) cells was variable. These readouts were broadly shared with the four other Khavinson peptides tested, so they are not unique to Chonluten (Avolio et al., 2022; PMID 35408963; doi:10.3390/ijms23073607).
- 03Context / classification (review): Chonluten is one of the 'Khavinson ultrashort peptides' from the St. Petersburg Institute of Bioregulation and Gerontology. The class-level hypothesis that such short peptides influence gene expression (cell/nuclear entry, DNA/histone interaction) is documented for other family members, not for the Glu-Asp-Gly tripeptide specifically (Khavinson et al., 2021, Molecules; PMID 34834147; doi:10.3390/molecules26227053).
- 04Non-conflation caution (review): Peer-reviewed lung-cell differentiation gene effects in the Khavinson literature (NKX2-1, SCGB1A1, SCGB3A2, FOXA1, FOXA2) are attributed to a different peptide, the tetrapeptide AEDL (Bronchogen) — NOT to Chonluten (EDG). Online vendor sources frequently conflate the two (Khavinson et al., 2021, Molecules; PMID 34834147; doi:10.3390/molecules26227053).
- 05Scope / evidence gap: No PubMed-indexed animal-model or human studies specific to Chonluten (Glu-Asp-Gly) were located. Respiratory-regeneration, mucin/ciliary, antioxidant/heat-shock, and anti-aging claims for this tripeptide appear only in non-peer-reviewed vendor/marketing material and are not supported by indexed primary research.
Evidence maturity varies by compound; much peptide research is preclinical (in vitro or animal-model). Where human data are limited, findings should be read as research observations, not clinical conclusions.
References
Literature references
Published research articles and sources related to Chonluten.
- 01Int J Mol Sci (2022) — Peptides Regulating Proliferative Activity and Inflammatory Pathways in the Monocyte/Macrophage THP-1 Cell Line View Sourceet al. (2022)
- 02Biomedicines (2025) — Overcoming Oral Cavity Barriers for Peptide Delivery Using Advanced Pharmaceutical Techniques and Nano-Formulation Platforms View Sourceet al. (2025)
- 03Sigma-Aldrich — Peptide Handling Guide (storage, reconstitution, and stability recommendations) View Source
- 04CDC (Subcut Injection PDF) — You Call the Shots: Subcutaneous Injection Technique View Source
- 05Signal Transduction and Targeted Therapy (2022) — Therapeutic peptides: current applications and future directions View Sourceet al. (2022)
- 06CDC — Preventing Unsafe Injection Practices (clinical safety guidance) View Source
- 07WHO (2021) — Guidance on preparation and administration of subcutaneous injections View Sourceet al. (2021)
- 08NCBI Bookshelf — Best practices for injection (asepsis, preparation, and administration) View Source
- 09Subcutaneous Drug Injection Review (PMC) — Pharmacologic considerations of the subcutaneous route View Source
- 10Alzheimer’s Drug Discovery Foundation (2015) — Epithalamin/Epithalon Evidence Summary (bioregulator peptide context) View Sourceet al. (2015)
- 11Pure Lab Peptides — Chonluten (20 mg) product page (quality and batch documentation) View Source
Research Considerations
Research considerations
Research Use Only - not for human or veterinary therapeutic use. Current evidence is limited to in vitro and/or animal-model research; human data are minimal or absent. Consult a licensed healthcare professional for any clinical decisions.
Factors noted in the research literature; not patient-specific medical advice.
Regulatory Status
Regulatory status
RUO
Comparisons
Comparisons
| Compound | Mechanism | Route | Status |
|---|---|---|---|
| Chonlutenthis | A short tripeptide bioregulator (Glu-Asp-Gly) studied for effects on bronchopulmonary tissue and modulation of inflammatory signaling in monocyte/macrophage models. | subcutaneous | Investigational / RUO |
| Cortagen | A synthetic tetrapeptide (Ala-Glu-Asp-Pro) of the Khavinson bioregulator class studied for neuroprotective and neuroregenerative activity, including peripheral nerve repair. | subcutaneous | Investigational / RUO |
| Epitalon (Epithalon) | A synthetic tetrapeptide (Ala-Glu-Asp-Gly) studied for activation of telomerase and modulation of pineal/melatonin and circadian pathways, of interest in geroprotection research. | subcutaneous | Investigational / RUO |
| FOXO4-DRI | A D-retro-inverso peptide designed to disrupt the FOXO4-p53 interaction in senescent cells, releasing p53 to selectively induce apoptosis of senescent cells (a senolytic mechanism). | subcutaneous | Investigational / RUO |
| Glutathione | An endogenous tripeptide (gamma-L-glutamyl-L-cysteinyl-glycine) functioning as a major intracellular antioxidant and redox buffer, supporting phase-II detoxification conjugation and neutralization of reactive oxygen species. | subcutaneous | Investigational / RUO |
| CJC-1295 | Binds to GHRH receptors to stimulate GH release. Modified structure provides extended duration of action (up to 7 days). | subcutaneous | Investigational / RUO |
| CJC-1295 DAC | A synthetic GHRH analog with a drug-affinity-complex (DAC) modification that binds serum albumin, greatly extending half-life and producing sustained stimulation of pituitary GH release. | subcutaneous | Investigational / RUO |
Attributes shown for research comparison only; not a statement of efficacy or therapeutic equivalence.
FAQ
Frequently asked questions
Chonluten is a synthetic tripeptide, Glu-Asp-Gly (research designation T-34), and one of the 'Khavinson ultrashort peptide' bioregulators developed at the St. Petersburg Institute of Bioregulation and Gerontology; in the literature it is described as associated with bronchial/respiratory epithelial tissue. It is handled here as a Research Use Only material, not a product for human use.
Limited. PubMed indexes essentially one study with Chonluten-specific data (an in vitro cell-culture experiment; Avolio et al., 2022, Int J Mol Sci; PMID 35408963; doi:10.3390/ijms23073607). No animal or human studies specific to this tripeptide were found, and most other information online is vendor-generated rather than peer-reviewed.
In human THP-1 monocytes/macrophages at 100 ng/mL, Chonluten reduced LPS-stimulated TNF and IL-6 release and increased ERK1/2 phosphorylation. These are cell-culture observations shared with several related peptides; they characterize behavior in a dish and do not demonstrate any clinical or in-vivo outcome (Avolio et al., 2022; PMID 35408963; doi:10.3390/ijms23073607).
Indexed primary research does not establish respiratory or regenerative outcomes for Chonluten. A common point of confusion: the lung-cell differentiation gene effects reported in the Khavinson literature belong to a different peptide, the tetrapeptide AEDL (Bronchogen), not to Chonluten (EDG) (Khavinson et al., 2021, Molecules; PMID 34834147; doi:10.3390/molecules26227053). This is an open research gap rather than an established effect.
The Khavinson framework proposes that ultrashort peptides can enter cells and modulate gene expression (for example, interactions with DNA or histones). For Chonluten specifically, this mechanism is hypothetical and has not been characterized in indexed literature; the gene-regulation evidence in this peptide family comes from other members (Khavinson et al., 2021, Molecules; PMID 34834147; doi:10.3390/molecules26227053).
No validated dosing exists, and no human dosing guidance can be provided. Research-reported amounts vary and appear mainly in non-peer-reviewed sources; the one indexed study used 100 ng/mL in cell culture, which does not translate to any in-vivo or human amount. Refer to the relevant protocol reference for any research-use parameters. This is not medical advice.
No peer-reviewed safety, tolerability, or observed-effects data specific to Chonluten in animals or humans were identified. Observed effects in research are confined to the in vitro cell-culture context described above. As an RUO material, it is not intended for human or veterinary use.
Research-use notice
Research Use Only. This educational content and calculation support is intended for private research documentation. It does not provide medical advice, human-use directions, or claims of safety or effectiveness.